GH
Secretagogues

01

Investigation

What is being claimed?

Natural GH optimization without “real HGH.” Fat loss, muscle, sleep, skin, recovery, anti-aging. CJC + ipamorelin as the default stack. Sermorelin as the legitimate FDA version. MK-677 as oral GH. Same benefits as tesamorelin without HIV.

People who already know one name often assume the others are rebrands. Chemistry, evidence tier, and regulatory object all change when the name changes.

02

Investigation

What is actually known?

Mechanism map

GHRH analogues (sermorelin, CJC-1295 ± DAC; tesamorelin as labeled comparator) act at the GHRH receptor. Ipamorelin and older GHRPs act at the ghrelin receptor. MK-677 is an oral ghrelin-receptor agonist, not a peptide injection. Two receptors in a stack is a mechanistic story, not automatically a clinical proof.

Evidence tiers

Tesamorelin: labeled package for a specific HIV-VAT indication (see that folio).

Sermorelin: historical FDA approval as Geref; branded product commercially discontinued; adult wellness uses lack a modern labeled outcome package.

Ipamorelin / CJC-1295: human data largely pharmacokinetic and limited clinical. Wellness body-composition and sleep claims run ahead of rigorous outcome RCTs. No approved wellness products.

MK-677: Phase 2–range work showing GH/IGF-1 and some body-composition signals; never FDA-approved; glucose, appetite, and edema themes appear in literature discussions.

CJC + ipamorelin stack: common in clinic culture. Not backed by a published high-quality RCT of that marketed combination for recomposition endpoints.

Raising GH in a study is not the same as proving the Instagram claim.

Regulatory / product

Common wellness uses for ipamorelin, CJC-1295, and MK-677 are not FDA-approved indications. Access is often compounding or gray-market. FDA has raised characterization and immunogenicity concerns for several injectable peptides; PCAC reviews in late 2024 voted against adding ipamorelin and CJC-1295 to the 503A Bulks List (advisory; verify current status before speaking in absolutes).

Sermorelin’s former approval is a real historical fact. It does not make today’s adult vial a labeled anti-aging drug. Product identity is clinical: what is in the bottle may not match the paper.

03

Investigation

What remains uncertain?

• Whether GH/IGF-1 rises under wellness protocols produce durable fat, muscle, or sleep benefits worth the risk and cost
• Long-term safety of compounded multi-peptide stacks
• How often clinic results are peptide vs training, diet, sleep coaching, and concurrent meds
• Stable legal compounding pathways as FDA policy evolves
• How to interpret IGF-1 numbers without a labeled target

04

Investigation

Why should an RD care?

Name literacy. Write down the exact agents. Ipamorelin ≠ CJC ≠ sermorelin ≠ MK-677 ≠ tesamorelin ≠ “HGH.”

Expectation literacy. Hormone rise isn’t recomposition proof. Stack popularity isn’t stack evidence.

Metabolic watch. Especially with MK-677: appetite, edema, glucose themes. Don’t assume injectable stacks are metabolically silent either.

Product quality is in-bounds. Compounded, clinic, or research-chem website? Uncertainty about contents is part of the risk conversation.

Nutrition still owns living well. Protein, resistance training, sleep, alcohol, shame detox. A peptide doesn’t retire those, and sometimes they were never started.

Tesamorelin pointer. The approved GH-axis body-composition conversation is a different folio.

Usable line: “Those names all touch the growth-hormone axis, but they aren’t one medicine. Some act like GHRH, some like ghrelin, and MK-677 is an oral drug that was studied but never approved. Raising GH in a lab study isn’t the same as proving fat loss or anti-aging. The popular CJC plus ipamorelin stack is common in clinics; it doesn’t have a solid published trial package for that stack.”